Ancient Mind-Body practice tested as fatigue fighter for men after cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 55 years * Previous diagnosis of local, regional, or metastatic cancer. If treated for cancer, prostate cancer therapy completed, 3+ months. If on ADT/ hormone manipulation, must be for 4 or more months * Previous diagnosis of small intestine, thyroid, oral, non-muscle invasive bladder, kidney/renal, lung, colon, rectum, soft tissue, or other cancer * Meet study criteria for fatigue: Medical Health Outcome Study Short Form Vitality/Fatigue subscale (SF-36 Vitality scale-4 items; 5 Likert scale) using a fatigue cut-off value of ≤13; or the Patient-Reported Outcomes Measurement Information System Fatigue scale (PROMIS Fatigue scale) using a cut-off value of ≥9 * Live within 75 miles of New Brunswick or Newark * Inactive (\<150 minutes of vigorous exercise/week within the past 3 months) * Has transportation to attend on-site classes and assessments Exclusion Criteria: * Patient Health Questionnaire PHQ-9 Score \>12 * Indication of suicidality from PHQ-9 reports that he has several or more days of "thoughts that you would be better off dead, or of hurting yourself." * Karnofsky performance status score of 50 or below * Current regular practice within the past year (2-3 times a week over a period of two months that is not interrupted) of BMT or other complementary and alternative medicine that shares similar principles of BMT. * Inability to speak and read English proficiently * Unable to understand informed consent * Current health conditions that may interfere with the intervention: respiratory, cardiovascular, or neurological problems unless released by a physician * Medical conditions or activities that can cause severe fatigue: Severe hearing loss that would cause difficulty following an instructor in a group setting, chronic fatigue syndrome, current major depression, alcohol use disorder, shift work * Prostate cancer that has metastasized to the liver, brain, or lungs * Currently receiving chemotherapy with VePesid, Cytoxan, Enzalutamide (XTANDI®), intravenous chemotherapy or radionucleotides (Strontium-89, Samarium (Quadramet®), Radium-223 (Xofigo®)), or other therapy (as confirmed by study team) * Unwilling to be randomized to study arms and/or commit to 12 weeks of classes and assessments * Have had a diagnosis of another cancer, unless: * Non-melanoma skin cancer or * Completed treatment AND cancer-free for 5 or more years. We will not include any of the following special populations: * Adults unable to consent * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners